Search results
Results from the WOW.Com Content Network
Congenital CMV cannot be diagnosed if the infant is tested more than one week after birth. [citation needed] Visually healthy infants are not routinely tested for CMV infection although only 10–20% will show signs of infection at birth [citation needed] though up to 80% may go onto show signs of prenatal infection in later life. If a pregnant ...
Valganciclovir is commonly used for treatment of cytomegalovirus (CMV) retinitis (eye infection may cause blindness) in people who have acquired immunodeficiency syndrome (AIDS). [7] Valganciclovir is also used to prevent cytomegalovirus disease in people who have received a heart, kidney, or kidney-pancreas transplant and who have a chance of ...
In infants that weigh under 1500 g, sepsis is the most common cause of death. Three to four percent of infants per 1000 births contract sepsis. The mortality rate from sepsis is near 25%. [36] Infected sepsis in an infant can be identified by culturing the blood and spinal fluid and if suspected, intravenous antibiotics are usually started.
Cidofovir, brand name Vistide, is a topical or injectable antiviral medication primarily used as a treatment for cytomegalovirus (CMV) retinitis (an infection of the retina of the eye) in people with AIDS. [4] [5] Cidofovir was approved for medical use in 1996. [6]
Diseases associated with HHV-5 include mononucleosis and pneumonia, [4] [5] and congenital CMV in infants can lead to deafness and ambulatory problems. [6] In the medical literature, most mentions of CMV without further specification refer implicitly to human CMV. Human CMV is the most studied of all cytomegaloviruses. [7]
The CMV pp65 assay is widely used for monitoring CMV infection and its response to antiviral treatment in people who are under immunosuppressive therapy and have had renal transplantation surgery, as the antigenemia results are obtained about 5 days before the onset of symptomatic CMV disease.
Mystery solved: Investigators find parents of newborn Jane Doe left in ditch in 1980 near St. Cloud
A phase 2 study of a recombinant gB protein subunit CMV-vaccine published in 2009 indicated an efficacy of 50% in seronegative women of childbearing age—thus the protection provided was limited and a number of subjects contracted CMV infection despite the vaccination. In one case congenital CMV was encountered. [2] [10]